menu
    • menu
    [{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"IMPACT Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"IMP1734","moa":"PARP-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ Eikon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eikon Therapeutics \/ Eikon Therapeutics"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"IMPACT Therapeutics, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"IMP1734","moa":"PARP-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ IMPACT Therapeutics, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Eikon Therapeutics \/ IMPACT Therapeutics, Inc"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Oncology","graph2":"Phase II","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eikon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Oncology","graph2":"Phase II","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Eikon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Seven and Eight","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Oncology","graph2":"Phase II","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ Seven and Eight","highestDevelopmentStatusID":"8","companyTruncated":"Eikon Therapeutics \/ Seven and Eight"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Seven and Eight Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"BDB018","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eikon Therapeutics \/ Eikon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Eikon Therapeutics \/ Eikon Therapeutics"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BDB018","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Eikon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EIK1001","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eikon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Eikon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Lux Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series D Financing","leadProduct":"EIK1001","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Eikon Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Injection","sponsorNew":"Eikon Therapeutics \/ Lux Capital","highestDevelopmentStatusID":"9","companyTruncated":"Eikon Therapeutics \/ Lux Capital"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EIK1001","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eikon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"IMPACT Therapeutics, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"EIK1004-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ IMPACT Therapeutics, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Eikon Therapeutics \/ IMPACT Therapeutics, Inc"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Cleave Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ Eikon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eikon Therapeutics \/ Eikon Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Eikon Therapeutics

    Menu

    Eikon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EIK1004-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : IMPACT Therapeutics, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

                            Details : EIK1004-001 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 02, 2025

                            Lead Product(s) : EIK1004-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : IMPACT Therapeutics, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EIK1001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Lux Capital

                            Deal Size : $350.7 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Eikon Secures $350.7M Series D to Advance Clinical Programs, Future Pipeline

                            Details : The financing aims to advance the company's pipeline, which includes lead product EIK1001, a systemically administered co-agonist of toll-like receptors 7/8 now in a Phase III for advanced melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 26, 2025

                            Lead Product(s) : EIK1001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Lux Capital

                            Deal Size : $350.7 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EIK1001

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of EIK1001-006 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Pat...

                            Details : EIK1001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 20, 2024

                            Lead Product(s) : EIK1001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMP1734

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : IMPACT Therapeutics, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

                            Details : IMP1734 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 12, 2024

                            Lead Product(s) : IMP1734

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : IMPACT Therapeutics, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EIK1001

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

                            Details : EIK1001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 07, 2024

                            Lead Product(s) : EIK1001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Cleave Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

                            Details : Through the acquisition, Eikon gains Cleave’s preclinical assets, including a large chemical library spanning multiple targets in the AAA (ATPases Associated with diverse cellular Activities) family of ATPases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Cleave Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMP1734

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : IMPACT Therapeutics, Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1...

                            Details : Under the collaboration, Eikon received an exclusive license from Impact to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 01, 2023

                            Lead Product(s) : IMP1734

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : IMPACT Therapeutics, Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BDB018,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Seven and Eight Biopharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to D...

                            Details : Under the terms of the agreement, Eikon Therapeutics is awarded global rights to develop and commercialize the company’s BDB018, a novel immune modulator agonists targeting toll-like receptor 7 and 8 (TLR7/8) being developed in advanced solid tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 01, 2023

                            Lead Product(s) : BDB018,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Seven and Eight Biopharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BDB018

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tu...

                            Details : BDB018 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 12, 2021

                            Lead Product(s) : BDB018

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eikon Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BDB001

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

                            Details : BDB001 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 29, 2021

                            Lead Product(s) : BDB001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth